ABSTRACT
Introduction/Aim: Anxiety and depression in adolescents with cystic fibrosis (CF) is 2-3 times higher than those in the general community. The COVID-19 pandemic has been shown to increase levels of distress and difficulties in secondary students in Western Australia (WA). We aimed to examine the prevalence of anxiety and depression symptoms in adolescents with CF living in WA during the pandemic and investigate associations with respiratory symptoms, lung function and quality of life. Method(s): Adolescents with CF aged between 12 and 18 years old were followed at Perth Children's Hospital (Western Australia) between October 2020 and October 2022. Adolescents completed the General Anxiety Disorder-7 (GAD-7) for anxiety and Patient Health Questionnaire-9 (PHQ-9) for depression when clinically stable. We assessed associations between depression and anxiety scores with respiratory symptoms from the Cystic Fibrosis Respiratory Symptoms Diary and Cystic Fibrosis Respiratory Infection Symptoms Scale (CFRSD-CRISS), lung function outcomes (forced expiratory volume in first second (FEV 1) and lung clearance index (LCI)), and quality of life outcomes from the health-related quality of life questionnaire (CFQ-R). Result(s): In 28 adolescents with CF, 39% had an elevated anxiety score (mild and above) and 28% had an elevated depression score (mild and above). No difference in scores was observed between males and females. Both the anxiety and depression scores correlated with the severity of respiratory symptoms from the CFRSD-CRISS questionnaire. Anxiety and depressions scores were not associated with either FEV 1 or LCI. Depressions scores were associated with most CFQ-R domains whilst anxiety scores were only associated with the social CFQ-R domain. Conclusion(s): Depression and anxiety were common in adolescents with CF in our centre. The results demonstrate the importance of depression/anxiety screening and psychological support for adolescents with CF and their families.
ABSTRACT
Background. The Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) study is following over 200 healthcare workers who have received the Pfizer-BioNTech BNT162b2 COVID-19 mRNA vaccine. A major aim of the study is to determine whether baseline antibody titers against the seasonal human coronaviruses are associated with altered levels of vaccine-induced antibody responses to SARS-CoV-2. Methods. Serial serum samples obtained pre-vaccination and 1 month after the second dose were tested for IgG antibodies against the full pre-fusion spike protein and the receptor binding domain (RBD) of SARS-CoV-2, as well as the full pre-fusion spike proteins of OC43, HKU1, 229E, and NL63. Antibodies were measured using highly sensitive and specific multiplex assays based on Luminex-xMAP technology. Results. Preliminary analyses of the first 103 subjects in whom we have 1 month post-vaccination serum demonstrate development of high IgG geometric mean titers (GMT) to both the full spike protein (GMT: 13,685, 12,014-15,589, 95% CI) and the RBD (GMT: 19,448, 17,264-21,908, 95% CI) of SARS-CoV-2 after the 2nd vaccine dose. Preliminary analysis demonstrates no association between baseline antibody titers against spike protein of OC43 and antibody titers against SARS-CoV-2 spike protein (Pearson's r-value= 0.13, P-value= 0.21) or RBD (Pearson's r-value= 0.09, P-value= 0.36) one month after vaccination. Future analyses will evaluate whether there is an association with baseline seasonal coronavirus antibody titers and either SARS-CoV-2 neutralization titers or anti-SARS-CoV-2 spike protein titers at 6 months after vaccination. Conclusion. These preliminary results suggest that baseline antibody responses to seasonal coronaviruses neither boost nor impede SARS-CoV-2 vaccine-induced antibody responses. Longitudinal sampling will enable assessment of vaccine durability and determination of whether baseline seasonal coronavirus antibody levels are associated with altered duration of detectable COVID-19 vaccine-induced antibody responses.
ABSTRACT
Early evidence of disproportionate COVID-19 infection and death rates in Native Hawaiian and Pacific Islander communities in the continental US raised concerns for similar disparities in Hawai'i, where these communities make up 25% of the state's population. Representatives from more than 40 different government, academic, institutional and community-based organizations partnered to form the Hawai'i Native Hawaiian and Pacific Islander COVID-19 Response, Recovery, and Resilience Team. The team consists of 5 committees including the Data & Research Committee. This committee is tasked with examining issues regarding the acquisition, quality, public reporting, and utilization of race/ethnicity-related health data used to inform priorities and guide resource allocation. Problems addressed by this committee include: inconsistency across agencies in the use of race identifiers, defaulting to the Office of Management and Budget standards which aggregated Native Hawaiian and Pacific Islanders, and methods of data collection and reporting by the Department of Health. Outcomes include: 2 forms with race categories that reflect the population of Hawai'i;the reporting of disaggregated data by the Department of Health;and conversations with testing sites, laboratories, and health institutions urging a standardized form for race/ethnicity data collection. The collection and reporting of disaggregated race/ethnicity data is critical to guiding organizations in addressing underlying inequities in chronic disease and social determinants of health that can exacerbate the adverse effects of COVID-19. The Data and Research Committee's network offers a community-based model for collaborative work that honors culture and ensures Native Hawaiian, Pacific Islander, and other minority populations are recognized and counted. ©Copyright 2021 by University Health Partners of Hawai‘i (UHP Hawai‘i).